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Abstracts / Biol Blood Marrow Transplant 20 (2014) S72eS90 S79median age of 16 (2-80) months at transplantation with a
median follow-up of 8.9 (3-22.6) years after last HCT. Post-
transplant leukocyte IDUA enzyme levels below the lower
reference were seen in 25% of patients due to mixed-
chimerism or the use of a carrier donor. Following successful
HCT, the clinical course of HS patients is strikingly improved,
evident in all organ systems. Residual disease burden is
present in the majority of the patients with high variability
between patients. A better cognitive status at HCT was a
major predictor for superior cognitive development after
HCT (ﬁgure 1). Signiﬁcant predictors for superior long-term
outcome in all organ systems were the presence of “normal
IDUA enzyme levels obtained after HCT” and a “younger
age at transplantation”. See the association between the
leukocyte IDUA enzyme level obtained after HCTand surgical
intervention for cord compression and growth, in ﬁgure 2
and 3 respectively.
Conclusion: Although HCT signiﬁcantly improved the
clinical course in HS patients, residual disease burden was
observed in the majority of transplanted HS patients.
Using exclusively non-carrier donors and accepting only
full donor-chimerism will improve the prognosis of
HS patients. Reducing the age at HCT through newborn
screening could further improve the outcomes of HS pa-
tients after HCT.83
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Allogeneic stem cell transplantation (alloSCT) remains the
only curative option for sickle cell disease (SCD). However, no
systematic analysis exists comparing cost and quality of life
(QOL) among this population. We investigated the QOL
outcomes and health care utilization associated with alloSCT
in children with SCD.
Internal ﬁnancial data from 2002-2011 was analyzed retro-
spectively across two groups e post-alloSCT patients
(>day+365) and patients with SCD referred for alloSCT and/
or HLA typed. Surviving alloSCT recipients (A) and SCD
controls (B) were surveyed with age appropriate Pediatric
Quality of Life Inventory (PedsQLa) and EuroQOL (EQ-5Da)Post-AlloSCT
(>D+365, group A)
Controls
(group B)
p-value
Mean outpatient visits 0.93 1.81 <0.0001
Mean outpatient cost ($) 831.10 739.2 0.840
Mean outpatient cost
per QOL ($/QALM)
723.67 442.16 0.3506
Mean inpatient visits 0.02 0.52 <0.0001
Length of stay 0.06 1.05 <0.0001
Mean inpatient cost ($) 293.80 2050.20 0.115
Mean inpatient cost
per QOL ($/QALM)
345.69 769.08 0.0023questionnaires. Group A siblings without SCD (C) were also
surveyed as unaffected controls. Mean QOL scores were
calculated for each group with a max score of 100. Utility
scores were determined based on EQ-5D responses. These
scores and costs for groups A and B were used to calculate
cost per quality adjusted life month (QALM) for the cohort of
patients surveyed. Wilcoxon test was used to determine
statistical signiﬁcance.
Group A, B, and C had 16 (mean age - 14yrs), 19 (mean age -
12yrs), and 14 children (mean age - 14yrs), respectively. SCD
therapy included hydroxyurea (group A n¼8, group B n¼10)
and chronic transfusions (group A n¼7, group B n¼2). Mean
PedsQL scaled scores were 83, 81, and 88, respectively. Mean
EQ-5D visual analogue scale scores were 92, 87, 96, respec-
tively. Mean utility scores were 0.87, 0.91, and 0.89, respec-
tively. All QOL scores were not statistically signiﬁcant (p ¼
0.2638). Healthcare utilization among groups A and B was
previously reported (see details in table below). The median
inpatient cost per QALM for group A was $0 and $514 for
group B (p ¼ 0.0023). Outpatient cost per QALM for group A
was $353 and $236 for group B (p ¼ 0.3506).
SCD patients’ post-alloSCT QOL scores are similar to unaf-
fected siblings, indicating that QOL has normalized. Controls
with SCD also had scores similar to unaffected controls.
However, a statistically signiﬁcant difference exists in the
inpatient cost per QALM post-alloSCT compared to controls
with SCD. Outpatient was not signiﬁcant which may reﬂect
the limitations of the study period as post-alloSCT QOL and
cost can change over time (Felder-Puig 2006; Majhail 2010).
Ultimately, this study provides the ﬁrst combined analysis of
QOL as an outcome and the economic impact of alloSCT for
pediatric SCD patients. Further analysis is ongoing to afﬁrm
that alloSCT is a beneﬁcial and cost effective management
option for patients.84
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Background: Children, adolescents, and young adults
(CAYA) with Acute Leukemia in third complete remission
